InSysBio creates a legal entity in UK

NEWS
Press-Release
August 15, 2018

August 15, 2018

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the registration of legal entity in UK. InSysBio UK (INSYSBIO UK LIMITED) is located in Edinburgh.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

April 2025
MoTuWeThFrSaSu
 
1
2
3
4
5
6
7
8
9
1. 09 Apr 2025 17:46 LikelihoodProfiler open-source package has undergone major redevelopment InSysBio releases a new version of LikelihoodProfiler.jl. LikelihoodProfiler represents a unified Julia package that can be used for practical identifiability analysis for complex computationally demanding QSP models.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
    
Upcoming Events
25.04
InSysBio to participate in AACR 2025
Tags
Latest News
09.04
InSysBio to release a new version of LikelihoodProfiler.jl
31.03
InSysBio to launch Immune Response Template version 3.7.0 for QSP modeling
19.03
InSysBio announces its collaboration with discoveric bio alpha
19.02
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
05.12
InSysBio to celebrate its 20-year anniversary